Trials / Recruiting
RecruitingNCT06850480
A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis
A Multicenter, Randomized, Double-blind, Double-simulated, Positive Parallel-control Phase III Clinical Trails of JP-1366（Zastaprazan Citrate） Tablets and Nexium® on Reflux Esophagitis
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 356 (estimated)
- Sponsor
- Livzon Pharmaceutical Group Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of JP-1366 tablets and Nexium® (Esomeprazole magnesium enteric-coated tablets) in subjects with reflux esophagitis.
Detailed description
To evaluate the efficacy and safety of JP-1366 tablets and Nexium® (Esomeprazole magnesium enteric-coated tablets) in subjects with reflux esophagitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JP-1366 simulation tablets | qd, last for 4-8 weeks |
| DRUG | Esomeprazole Magnesium (Nexium) simulation tablets | qd, last for 4-8 weeks |
Timeline
- Start date
- 2024-12-05
- Primary completion
- 2025-04-15
- Completion
- 2025-04-30
- First posted
- 2025-02-27
- Last updated
- 2025-02-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06850480. Inclusion in this directory is not an endorsement.